Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

APPOINTMENT OF INVESTIGATOR AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Sunho Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements (the "**Announcements**") of the Company dated March 27, 2026, March 30, 2026, April 1, 2026, April 21, 2026, April 27, 2026, May 3, 2026 and May 26, 2026 in relation to, among other things, the delay in publication of 2025 Annual Results, the suspension of trading in the Shares, the Resumption Guidance, the establishment of an independent investigation committee (the "**Independent Investigation Committee**") and the appointment of Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen as the initial members of the Independent Investigation Committee. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

APPOINTMENT OF INVESTIGATOR

On June 17, 2026, the Independent Investigation Committee appointed CLA Advisory (Hong Kong) Limited as the independent forensic investigator (the "**Investigator**") to undertake the Independent Investigation into the Matters. Factors considered by the Independent Investigation Committee in respect of the appointment of Investigator include, among other things:

(i) the Investigator is an independent third party not connected with any of the substantial Shareholders, Directors, or the Company's outgoing or incoming auditors. The Investigator has confirmed it does not have any prior or existing business relationship with the Group that would reasonably be considered to impair its independence in performing the Independent Investigation;

(ii) the Investigator will deploy an 8-person dedicated forensic team to undertake the Independent Investigation. The engagement team is led by a senior partner with over 18 years of audit and forensic experience. All engagement team members possess extensive experience in complex financial investigations in both Hong Kong and Mainland China;

(iii) the engagement team has an extensive track record of successfully undertaking independent forensic investigations for companies listed on the Stock Exchange; and

(iv) the Investigator has committed to a pragmatic timetable which aligns with the Company's timetable for fulfilment of the Resumption Guidance.

Based on the above, the Independent Investigation Committee concluded that the Investigator is independent and possesses the credentials, qualifications, experience and resources to conduct the Investigation.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of the progress and any material developments or key findings and views regarding the Independent Investigation and the compliance with the Resumption Guidance as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, June 17, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.